Global Finance News
03 Nov 2025, 14:54
IDEXX Lifts 2025 Outlook on Double-Digit Q3 Growth
IDEXX Laboratories (Nasdaq: IDXX) posted Q3 revenue of $1.105 billion, up 13% reported (12% organic), with CAG Diagnostics recurring revenue up 11% reported (10% organic) and over 1,700 inVue Dx placements. EPS rose 21% to $3.40, with ~100 bps operating margin expansion. The company raised 2025 guidance: revenue to $4.27–$4.30 billion (9.6%–10.3% reported; 8.8%–9.5% organic), CAG Diagnostics recurring growth to 8.3%–9.0% reported (7.5%–8.2% organic), and EPS to $12.81–$13.01 (about $0.33 higher at the midpoint).
IDEXX Laboratories (Nasdaq: IDXX) posted Q3 revenue of $1.105 billion, up 13% reported (12% organic), with CAG Diagnostics recurring revenue up 11% reported (10% organic) and over 1,700 inVue Dx placements. EPS rose 21% to $3.40, with ~100 bps operating margin expansion. The company raised 2025 guidance: revenue to $4.27–$4.30 billion (9.6%–10.3% reported; 8.8%–9.5% organic), CAG Diagnostics recurring growth to 8.3%–9.0% reported (7.5%–8.2% organic), and EPS to $12.81–$13.01 (about $0.33 higher at the midpoint).
